Lisinopril is one of the most commonly prescribed blood pressure medications in the country, which is exactly why job candidates and employees sometimes wonder whether it could trigger a positive result on a pre employment or workplace drug screen. The short answer is that standard workplace drug test panels are not built to look for blood pressure medications at all, and there is no published evidence that lisinopril cross reacts with the immunoassay chemistry used in those panels. This article explains what lisinopril actually is, why it falls outside the scope of a drug test, what a lab would need to do to find it on purpose, and what happens procedurally when a result is questioned.
What lisinopril is and how it is classified
Lisinopril is an angiotensin converting enzyme (ACE) inhibitor, a class of medication prescribed for high blood pressure, heart failure, and to improve survival after certain heart attacks. It works by blocking the enzyme that narrows blood vessels, which lowers blood pressure and reduces strain on the heart. The current prescribing information and patient labeling for lisinopril is published on DailyMed, the National Library of Medicine's repository of official drug labels, and it describes the drug strictly in cardiovascular terms, with no mention of abuse potential, scheduling, or drug testing relevance. You can review the lisinopril label on DailyMed directly.
Is lisinopril a controlled substance
No. Lisinopril does not appear on any federal schedule of controlled substances. The Drug Enforcement Administration maintains the schedules of controlled substances in the Code of Federal Regulations, and ACE inhibitors as a class are absent from that list because they carry no recognized potential for abuse or dependence. You can confirm the current federal schedules directly at 21 CFR Part 1308, Schedules of Controlled Substances, where lisinopril and other ACE inhibitors are not listed under Schedule I, II, III, IV, or V. That absence is part of why blood pressure medications are not something workplace testing programs attempt to screen for.
Does lisinopril appear on standard 5, 10, or 12 panel immunoassay tests
Workplace immunoassay panels are built around a fixed list of drug classes, not around every medication a person might take. A 5 panel test typically screens for marijuana metabolites, cocaine metabolites, opiates, amphetamines, and phencyclidine. A 10 or 12 panel test adds classes such as benzodiazepines, barbiturates, methadone, methadone metabolite, methaqualone, propoxyphene, MDMA, and sometimes oxycodone. Lisinopril does not belong to any of these drug classes. It is not an opioid, not an amphetamine, not a benzodiazepine, and not chemically related to any analyte those antibody based immunoassays are designed to detect.
| Panel class the strip or cup checks | Is lisinopril part of this class | Would a standard immunoassay flag lisinopril |
|---|---|---|
| THC (marijuana metabolite) | No | No |
| Opiates and opioid metabolites | No, lisinopril is an ACE inhibitor | No |
| Amphetamines and methamphetamine | No | No |
| Benzodiazepines and barbiturates | No | No |
| Cocaine metabolite, PCP, MDMA | No | No |
What does the published cross reactivity evidence say
Immunoassay manufacturers and independent researchers have published cross reactivity data for a range of common prescription drugs against standard drug test antibodies, because false positives from legitimate medications are a known limitation of screening immunoassays. For lisinopril specifically, there is no published cross reactivity evidence showing that it reacts with any standard employment drug test antibody class. The drug's own labeling on DailyMed does not list drug test interference as a known effect, and no cross reactivity study on file with the National Library of Medicine or the FDA identifies lisinopril as a cause of a false positive on any panel class. If new data were to emerge, it would appear in the drug's labeling or in a peer reviewed study; as of now, the honest and accurate statement is that there is no published cross reactivity between lisinopril and standard workplace drug test immunoassays.
Could a lab detect lisinopril if someone specifically tested for it
Standard urine cups, oral fluid tests, and dip cards used for pre employment and workplace testing are not designed to detect lisinopril, and a result will never come back as "positive for lisinopril" because the drug is not one of the analytes those panels are built to find. A clinical or forensic toxicology lab could theoretically identify lisinopril in blood or urine using targeted liquid chromatography tandem mass spectrometry (LC/MS/MS), but that kind of testing is ordered for clinical adherence monitoring or specific investigations, not for routine employment screening. It is a different test entirely from the immunoassay cups and dip cards used in a typical drug free workplace program.
How GC/MS and LC/MS confirmation fits into the process
When an initial immunoassay screen comes back non negative, federally regulated and most private sector drug testing programs send the specimen for confirmation using gas chromatography mass spectrometry (GC/MS) or liquid chromatography tandem mass spectrometry (LC/MS/MS). Confirmation testing identifies the exact molecule present rather than relying on antibody binding, which is why it is considered the gold standard for resolving a presumptive screening result. Because lisinopril is not a target analyte on any standard panel, there is no scenario where lisinopril would cause an initial screen to flag in the first place, so confirmation testing is not something a lisinopril prescription would typically trigger. Confirmation remains the backstop for any drug class where cross reactivity is a known possibility, which is a separate question from lisinopril's actual pharmacology.
The dilute specimen question
A more realistic question for people managing blood pressure is dilute specimens, not false positives. Patients are sometimes advised to increase water intake, and some blood pressure regimens pair an ACE inhibitor like lisinopril with a diuretic such as hydrochlorothiazide, which increases urine output. Either habit can lower the creatinine and specific gravity of a urine specimen enough to classify it as dilute under federal testing rules. A dilute specimen is not the same thing as a positive result, and by itself it is not evidence of tampering, but federal rules at 49 CFR Part 40 set out exactly how a dilute negative or dilute positive result must be handled, including when a recollection under direct observation is required. The Medical Review Officer provisions in 49 CFR Part 40, Subpart G cover dilute specimen handling directly. Our related article on dilute drug test results walks through what employers need to know when a result comes back dilute.
MRO review and prescription documentation
Any time a screening result is non negative for a regulated drug class, the specimen goes to a Medical Review Officer, a licensed physician trained to interpret laboratory results and determine whether a legitimate medical explanation exists. The MRO process is defined in detail at 49 CFR Part 40, Subpart G, which spells out how an MRO contacts the employee, reviews prescription documentation, and decides whether a result should be verified positive, cancelled, or reported negative. Because lisinopril is not a target analyte, it would not independently produce a non negative screen that requires this kind of review, but any employee taking prescription medication of any kind should keep documentation available and be prepared to discuss it with the MRO if a different drug class on the panel comes back non negative for an unrelated reason. Employers who want a fuller walkthrough of this process can read our guide to the Medical Review Officer process.
What employers should do with a disputed result
If an employee disputes a result and raises a prescription as the explanation, the appropriate path is the same regardless of which drug is involved: route the result to the MRO or a qualified reviewing physician, request supporting prescription documentation, and let the verification process run its course rather than making an independent medical judgment in house. Employers generally should not attempt to interpret toxicology results themselves or decide informally whether a medication explains a result. State laws and company policy on how disputes are documented and communicated can vary, so employers should confirm their specific obligations with counsel or their testing program administrator rather than relying on a blanket rule.
Frequently asked questions
Is lisinopril a controlled substance
No. Lisinopril does not appear on the DEA's schedules of controlled substances published in 21 CFR Part 1308. It is a prescription blood pressure medication with no recognized abuse potential.
Will lisinopril cause a false positive on a 5 panel or 10 panel drug test
There is no published cross reactivity evidence showing lisinopril affects any standard immunoassay drug class. It is not chemically related to THC, opiates, amphetamines, benzodiazepines, or any other analyte those panels target.
Can a drug test specifically detect lisinopril
Standard workplace cups, dip cards, and oral fluid tests are not built to look for lisinopril. A lab could identify it with targeted LC/MS testing, but that is a different kind of test used for clinical monitoring, not routine employment screening.
Could lisinopril cause a dilute urine specimen
Increased water intake or a combination blood pressure regimen that includes a diuretic can lower urine concentration enough to register as dilute. Dilute results are handled under specific federal rules and are not the same as a positive result.
What should an employee do if asked about a disputed drug test result
Provide prescription documentation to the Medical Review Officer when asked and let the verification process run through its normal steps rather than trying to resolve the question outside that process.
Does a prescription automatically clear a non negative drug test result
Not automatically. The MRO reviews the specific drug class that triggered the non negative result and the documentation provided before deciding whether a legitimate medical explanation applies to that result.
Employers building or maintaining a drug free workplace program can review cup and dip card options in our drug test cup collection.
This article is general information, not legal or medical advice. Employers and employees should consult qualified counsel or a Medical Review Officer for guidance specific to their situation.
